샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795344

세계의 육종 치료 시장

Sarcoma Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 180 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

육종 치료 세계 시장은 2030년까지 36억 달러에 달할 전망

2024년에 23억 달러로 추정되는 육종 치료 세계 시장은 2024-2030년 분석 기간 동안 CAGR 7.6%로 성장하여 2030년에는 36억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 연부 육종은 CAGR 9.0%를 기록하며 분석 기간 종료시에는 24억 달러에 달할 것으로 예측됩니다. 골육종 부문의 성장률은 분석 기간 동안 CAGR 5.1%로 추정됩니다.

미국 시장은 6억 3,090만 달러로 추정, 중국은 CAGR 12.1%로 성장할 것으로 예측

미국의 육종 치료 시장은 2024년에는 6억 3,090만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 12.1%로 2030년까지 7억 7,060만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.7%와 7.3%로 예측됩니다. 유럽에서는 독일이 CAGR 5.0%로 성장할 것으로 예측됩니다.

세계의 육종 치료 시장 - 주요 동향과 촉진요인 정리

육종 치료 시장은 왜 고정밀하고 아형에 특화된 접근법으로 진화하고 있는가?

간엽 조직에서 발생하는 다양한 악성 종양군인 육종은 희귀성, 조직학적 다양성, 생물학적 예측 불가능성으로 인해 여전히 가장 복잡한 종양학적 분류 중 하나입니다. 골육종, 유잉육종에서 평활근육종, 지방육종, 활막육종에 이르기까지 70개 이상의 조직형이 확인되고 있으며, 치료 관리에는 고도로 조정된 다학제적 접근이 요구됩니다. 지난 10년간 종양유전체학, 면역종양학, 희귀암 연구비의 발전으로 일반 화학요법에서 아형별 정밀 표적 치료제로의 점진적이지만 큰 전환이 이루어졌습니다.

전통적으로 치료 요법은 안트라사이클린 기반 화학요법, 특히 독소루비신 단독요법 또는 이포스파미드와 병용요법에 크게 의존해 왔습니다. 그러나 일부 육종, 특히 전이성 또는 재발성 육종의 경우, 반응률은 여전히 제한적입니다. 이 때문에 종양학 연구자들은 특정 육종 아형에 특이적인 유전자 변이, 전좌 또는 신호전달 경로를 억제하는 표적 치료제를 개발하게 되었습니다. 예를 들어, 다중 티로신 키나아제 억제제인 파조파닙은 현재 비지방세포성 연부 육종에 대한 승인을 받았으며, 이마티닙은 KIT 또는 PDGFRA 돌연변이가 있는 소화관 간질 종양(GIST) 치료에 혁명을 일으켰습니다. 이러한 획기적인 치료법은 육종 치료를 맞춤형 바이오마커 기반 치료의 영역으로 꾸준히 변화시키고 있습니다.

어떤 새로운 치료법이 아형 간 육종 치료를 재구성하고 있는가?

육종 파이프라인에는 분자표적 치료제와 면역치료제 두 가지 경로를 통해 새로운 치료제가 진입하고 있습니다. 티로신 키나아제 억제제(TKI)는 수용체 및 융합 단백질의 조절 이상이 알려진 육종 치료의 중심이 되고 있습니다. 예를 들어, 레고라페닙과 카보잔티닙은 각각 GIST와 골육종에 사용되어 1차 치료제에 반응하지 않는 환자에서 유망한 활성을 보이고 있습니다. 지방육종과 평활근종에 승인된 트라벡테딘은 DNA 결합과 종양 미세환경 조절을 통해 세포독성 작용을 발휘합니다. 에리브린, 랄로트렉티닙(NTRK 융합 유전자 양성 육종용) 등의 신약은 특히 화학요법 내성 변이형 육종에서 치료의 폭을 넓혀주고 있습니다.

면역치료는 육종 영역에서 점점 더 활발해지고 있지만, 반응은 아형에 따라 달라집니다. PD-1/PD-L1을 표적으로 하는 체크포인트 억제제는 미분화 다형성육종(UPS), 폐포성 연부 육종 등 특정 육종에서 지속적인 반응을 보이고 있습니다. 난치성 환자를 대상으로 CTLA-4 억제제, CAR-T 세포 치료제, 종양침윤림프구(TIL) 치료제에 대한 임상시험도 진행 중입니다. 면역 반응성 육종에 대한 보조 전략으로, 아직 연구 중이지만 입양 세포 요법과 암 백신이 평가되고 있습니다. 또한, 현재 진행 중인 혈관신생 억제제, HDAC 억제제, DNA 손상 반응 조절제의 연구로 특히 기존 화학요법과의 병용 치료의 가능성이 확대되고 있습니다.

첨단 육종 치료의 수요를 주도하는 환자 집단과 세계 시장은 어떤 환자 집단과 시장인가?

육종은 전체 성인 암의 1% 미만이지만, 소아 및 청소년 환자 집단에서 불균형적으로 큰 비중을 차지합니다. 유잉육종, 횡문근육종, 골육종 등 소아 육종은 20세 미만에서 많이 발생하며, 효과와 장기적인 안전성의 균형을 고려한 치료가 필요합니다. 성인 집단에서는 연부 육종이 주를 이루며, 종종 적극적인 전신 치료가 필요한 진행성 병변을 보이는 경우가 많습니다. 재발성 또는 전이성 육종 환자의 경우, 치료 시작 후 1년 이내에 표준치료가 소진되는 경우가 많으며, 2차 및 3차 치료 옵션에 대한 수요가 특히 높습니다.

지역적으로는 북미와 유럽이 주요 시장으로, 탄탄한 임상시험 인프라, 희귀질환 연구 자금, 분자진단에 대한 접근성을 바탕으로 성장하고 있습니다. 미국에는 육종 소개 센터와 환자 지원 단체가 집중되어 있으며, 의약품 개발 촉진에 적극 나서고 있습니다. 유럽 국가들은 육종에 특화된 등록과 범유럽 임상연구 네트워크의 혜택을 누리고 있습니다. 아시아태평양에서는 일본과 한국이 육종 전문 의약품 파이프라인을 확장하고 있으며, 인도와 중국은 의료 접근성 향상과 종양 프로파일링 기능으로 진단율이 상승하고 있습니다. 라틴아메리카와 중동은 특히 화학요법 기반 치료에서 바이오시밀러와 비용 효율적인 육종 치료 옵션의 중점 지역으로 부상하고 있습니다.

육종 치료 시장 성장을 촉진하는 주요 요인은 무엇인가?

육종 치료제 시장의 성장은 질병에 대한 인식 개선, 분자진단 약물의 채택 확대, 생물학적 제제 접근성 확대, 희귀암 연구의 지속적인 장려 등 몇 가지 중요한 요인에 의해 이루어지고 있습니다. 생검 방법의 개선과 면역조직화학, FISH, 차세대염기서열분석(NGS)에 대한 접근으로 육종 아형을 보다 빠르고 정확하게 진단할 수 있게 되었고, 종양 전문의는 보다 효과적으로 치료를 조정할 수 있게 되었습니다. 동반진단 및 바이오마커 기반 치료 프로토콜의 도입으로 제약사들은 아형에 특화된 임상시험과 희귀질환 치료제 개발에 투자하고 있습니다.

또한, FDA, EMA 등 규제기관이 육종 치료제를 희귀질환 치료제로 지정하면 개발기업은 세액공제, 시장 독점권, 신속심사 등의 인센티브를 받을 수 있습니다. 이 프로그램들은 연부 육종과 골육종을 표적으로 하는 실험적 약물 파이프라인을 촉진했습니다. 환자 지원 단체와 세계 희귀암 얼라이언스는 인지도를 높이고, 자금 조달 및 연구 참여를 촉진하여 임상시험 모집과 규제 당국의 승인을 보다 신속하게 받을 수 있도록 돕고 있습니다. 마지막으로, 의료 지불자는 육종 관리에서 표적 치료의 비용 대비 효과의 균형을 인식하기 시작했으며, 특히 실제 데이터가 무진행 생존기간과 삶의 질 개선을 뒷받침하고 있습니다. 이러한 시너지 효과로 세계 육종 치료제 시장은 탄탄한 성장 기반을 구축하고 있습니다.

부문

유형(연부 육종, 골육종)

조사 대상 기업 사례

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Deciphera Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG(Genentech)
  • Fresenius Kabi AG
  • GSK plc
  • Ipsen S.A.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Ltd.
  • Pfizer Inc.
  • Sanofi S.A.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.28

Global Sarcoma Therapeutics Market to Reach US$3.6 Billion by 2030

The global market for Sarcoma Therapeutics estimated at US$2.3 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Soft Tissue Sarcoma, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Osteosarcoma segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$630.9 Million While China is Forecast to Grow at 12.1% CAGR

The Sarcoma Therapeutics market in the U.S. is estimated at US$630.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$770.6 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Sarcoma Therapeutics Market - Key Trends & Drivers Summarized

Why Is the Sarcoma Therapeutics Landscape Evolving Toward Precision and Subtype-Specific Approaches?

Sarcoma, a diverse group of malignancies arising from mesenchymal tissues, remains one of the most complex oncologic categories due to its rarity, histological diversity, and biological unpredictability. With over 70 identified histological subtypes, ranging from osteosarcoma and Ewing sarcoma to leiomyosarcoma, liposarcoma, and synovial sarcoma, therapeutic management demands a highly tailored and multidisciplinary approach. The past decade has seen a gradual but significant shift from generalized chemotherapeutic regimens to subtype-specific and precision-targeted therapies, driven by advancements in tumor genomics, immuno-oncology, and rare cancer research funding.

Traditionally, treatment regimens have relied heavily on anthracycline-based chemotherapy, especially doxorubicin, either as monotherapy or in combination with ifosfamide. However, response rates remain limited in several sarcoma types, particularly those with metastatic or relapsed disease. This has prompted oncology researchers to develop targeted therapies that inhibit specific genetic mutations, translocations, or signaling pathways unique to certain sarcoma subtypes. For example, pazopanib, a multi-tyrosine kinase inhibitor, is now approved for non-adipocytic soft tissue sarcoma, while imatinib has revolutionized the treatment of gastrointestinal stromal tumors (GIST) harboring KIT or PDGFRA mutations. These breakthroughs are steadily transforming sarcoma therapeutics into a domain of individualized, biomarker-driven care.

What Emerging Therapies Are Reshaping Sarcoma Treatment Across Subtypes?

Novel therapeutics are entering the sarcoma pipeline through both targeted and immunotherapeutic pathways. Tyrosine kinase inhibitors (TKIs) continue to be central to managing sarcomas with known receptor or fusion protein dysregulation. For instance, regorafenib and cabozantinib are used in GIST and osteosarcoma respectively, showing promising activity in patients unresponsive to first-line agents. Trabectedin, approved for liposarcoma and leiomyosarcoma, exerts cytotoxic effects through DNA binding and modulation of the tumor microenvironment. Newer agents such as eribulin and larotrectinib (for NTRK fusion-positive sarcomas) are expanding the scope of treatment, particularly in chemoresistant variants.

Immunotherapy is gaining momentum in the sarcoma space, although responses vary across subtypes. Checkpoint inhibitors targeting PD-1/PD-L1 have shown durable responses in certain sarcomas like undifferentiated pleomorphic sarcoma (UPS) and alveolar soft part sarcoma. Trials are also investigating CTLA-4 inhibitors, CAR-T cell therapies, and tumor-infiltrating lymphocyte (TIL) therapies in refractory patients. Adoptive cell therapies and cancer vaccines, though still investigational, are being evaluated as adjunct strategies for immune-responsive sarcomas. Furthermore, ongoing research into angiogenesis inhibitors, HDAC inhibitors, and DNA damage response modulators is providing additional avenues for treatment, especially in combination with existing chemotherapy backbones.

Which Patient Populations and Global Markets Are Driving Demand for Advanced Sarcoma Therapies?

Although sarcomas constitute less than 1% of all adult cancers, they represent a disproportionately higher burden in pediatric and adolescent populations. Pediatric sarcomas such as Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma are more prevalent in individuals under 20 years of age, necessitating therapies that balance efficacy with long-term safety. In adult populations, soft tissue sarcomas dominate and often present with advanced-stage disease requiring aggressive systemic therapy. The need for second-line and third-line treatment options is particularly high among patients with recurrent or metastatic sarcomas, who often exhaust standard therapies within the first year of treatment.

Regionally, North America and Europe are the leading markets for sarcoma therapeutics, supported by robust clinical trial infrastructure, rare disease research funding, and access to molecular diagnostics. The U.S. sees a concentration of sarcoma referral centers and patient advocacy groups actively involved in accelerating drug development. European countries benefit from sarcoma-specific registries and pan-European clinical research networks. In Asia-Pacific, Japan and South Korea are expanding their sarcoma-focused drug pipelines, while India and China are witnessing a rise in diagnostic rates driven by improving healthcare access and tumor profiling capabilities. Latin America and the Middle East are emerging as focus regions for biosimilar and cost-effective sarcoma treatment options, especially for chemotherapy-based care.

What Are the Main Drivers Accelerating Market Growth for Sarcoma Therapeutics?

The growth in the sarcoma therapeutics market is driven by several critical factors, including rising disease awareness, increasing molecular diagnostic adoption, expanded access to biologics, and continued rare cancer research incentives. Improved biopsy practices and access to immunohistochemistry, FISH, and next-generation sequencing (NGS) are enabling earlier and more accurate diagnosis of sarcoma subtypes, allowing oncologists to tailor therapy more effectively. The introduction of companion diagnostics and biomarker-driven treatment protocols is pushing pharmaceutical companies to invest in subtype-specific trials and orphan drug development.

Additionally, the designation of sarcoma drugs as orphan products by regulatory bodies such as the FDA and EMA provides developers with incentives such as tax credits, market exclusivity, and expedited review pathways. These programs have fueled a pipeline of experimental drugs targeting both soft tissue and bone sarcomas. Patient advocacy organizations and global rare cancer alliances are enhancing visibility, fundraising, and research participation, thereby facilitating faster trial recruitment and regulatory approvals. Lastly, healthcare payers are beginning to recognize the cost-benefit balance of targeted therapies in sarcoma management, particularly as real-world data supports improved progression-free survival and quality of life outcomes. These synergistic developments are establishing a solid growth foundation for the global sarcoma therapeutics market.

SCOPE OF STUDY:

The report analyzes the Sarcoma Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Soft Tissue Sarcoma, Osteosarcoma)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Deciphera Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG (Genentech)
  • Fresenius Kabi AG
  • GSK plc
  • Ipsen S.A.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Ltd.
  • Pfizer Inc.
  • Sanofi S.A.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Sarcoma Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Unmet Need in Rare and Heterogeneous Sarcoma Subtypes Propels Therapeutic Innovation
    • Expansion of Precision Oncology Approaches Strengthens Market for Molecularly Targeted Sarcoma Therapies
    • Increased Use of Multimodal Treatment Regimens Drives Demand for Drug Combinations
    • Rising Adoption of Immunotherapy in Advanced Sarcoma Cases Fuels Clinical Trial Activity
    • Development of Selective TKIs and mTOR Inhibitors Expands Treatment Options for Metastatic Disease
    • Growth in Pediatric and Adolescent Sarcoma Cases Spurs Age-Specific Drug Development
    • Orphan Drug Incentives and Regulatory Flexibility Enhance Commercial Viability of Novel Agents
    • Increased Role of Genomic Profiling in Sarcoma Management Expands Scope for Personalized Therapies
    • Collaborations Between Cancer Centers and Biotech Firms Accelerate Pipeline Diversification
    • Use of Companion Diagnostics and Biomarker-Based Stratification Enhances Therapy Response Rates
    • Growing Investment in Cell Therapy and CAR-T Research for Sarcomas Expands Experimental Treatment Pathways
    • Expansion of Clinical Trials in Europe and Asia Improves Global Patient Access to Investigational Drugs
    • Integration of AI in Drug Repurposing Initiatives Accelerates Discovery in Ultra-Rare Sarcoma Subtypes
    • Patient Advocacy and Rare Cancer Networks Propel Policy Support for Accelerated Drug Approval
    • Real-World Evidence and Registry Data Strengthen Reimbursement for Targeted Sarcoma Treatments
    • Shift Toward Maintenance and Recurrence Prevention Therapies Expands Long-Term Treatment Models
    • Adoption of Tumor-Agnostic Therapies Opens New Avenues in Sarcoma With Specific Mutations
    • Increased Demand for Cost-Effective Off-Patent Therapies Spurs Biosimilar Entry in First-Line Settings
    • Cross-Border Research Consortia Support Innovation in Global Sarcoma Therapeutic Pipelines
    • Academic-Industry Co-Development Models Sustain Development in Low-Commercial Viability Subtypes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sarcoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sarcoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Osteosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Osteosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Osteosarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • JAPAN
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • CHINA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • EUROPE
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Sarcoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • FRANCE
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • GERMANY
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Sarcoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • INDIA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Sarcoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Sarcoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • AFRICA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제